The phase 3 IDHENTIFY study failed to show OS benefit with enasidenib compared to standard treatment options in IDH2mut, r/r AML (BMS press release)
The phase 3 IDHENTIFY study failed to show OS benefit with enasidenib compared to standard treatment options in IDH2mut, r/r AML (BMS press release)
The confirmatory CROWN study compared lorlatinib to crizotinib in tx-naïve, ALKpos NSCLC. The study met its’ primary endpoint (PFS by BIRC) at interim analysis. Data has not been presented (Pfizer press release).
Interim analysis of the phase 3 ADAURA study showed a significant improvement in DFS, and study was unblinded early in April 2020 (AZ press release)
